Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2021 > Vol 2, №2 (2021) > Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases

Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases

Ekaterina A. Butorova , Olga V. Stukalova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Purpose. The aim of this work is to show the capabilities of late gadolinium enhancement cardiac magnetic resonance imaging (MRI) in the diagnosis of a rare disease such as cardiac amyloidosis.
Materials and methods. Demonstration of clinical cases detecting cardiac amyloidosis using MRI.
Results. Contrast-enhanced cardiac MRI revealed patterns characteristic of cardiac amyloidosis. 
Conclusion. Cardiac MRI with late gadloinium enhancement is the method of choice in the diagnosis of cardiac amyloidosis.

Key words: amyloidosis, heart, MRI, late gadloinium enhancement.

About the Author

Ekaterina A. Butorova 1 , Olga V. Stukalova 1

1 National Medical Research Center of Cardiology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

References

1. Merlini G, Westermark P. The systemic: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159–78.
2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemicamyloidosis. Lancet 2016; 387 (10038): 2641–54. 
3. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012; 98: 1546–54.
4. Rapezzi C, Quarta CC, Riva L et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7: 398–408. 
5. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45: 107–37.
6. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration: analysis of four years’ experience. Am J Med. 1987; 82: 412–4.
7. Garcia-Pavia P, Comin-Colet J, Barriales-Villa R et al. Comments on the 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. A critical view from the perspective of Spanish cardiology. Rev Esp Cardiol 2015; 68: 4–9.
8. Mavrogeni SI, Vartela V, Ntalianis A et al. Cardiac amyloidosis: in search of the ideal diagnostic tool. Herz 2019. 
9. González-López E, Gallego-Delgado M, Guzzo-Merello G et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36 (38): 2585–94.
10. Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsydiagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404–12.
11. Ruberg FL, Appelbaum E, Davidoff R et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Amer J Cardiol 2009; 103 (4): 544–9. 
12. White SK, Sado DM, Flett AS, Moon J. Characterising the myocardial interstitial space: the clinical relevance non-invasive imaging. Heart 2012; 98: 773–9.
13. Aquaro GD, Pugliese NR, Perfetto F et al. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. Int J Cardiovasc Imaging 2014; 30 (6): 1105–15.
14. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155–64.
15. Stukalova OV. Magnetic resonance imaging of the heart with delayed contrast is a new method for diagnosing heart diseas-es. Russian Electronic Journal of Radiation Diagnostics. 2013; 3: 7–18 (in Russian).
16. Sipe JD, Benson MD, Buxbaum JN et al; Nomenclature Committee of the International Society of Amyloidosis. Amyloid fi bril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012; 19: 167–70.
17. Chatzantonis G, Bietenbeck M, Elsanhoury A et al. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 2020. DOI: 10.1007/s00392-020-01771-1
18. Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022–30.
19. Ana Martinez-Naharro, Thomas A. Treibel, Amna Abdel-Gadir et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol 2017; 70 (4): 466–77. 
20. Fontana M, Banypersad SM, Treibel TA et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and lightchain amyloidosis: a cardiac MR imaging study. Radiology 2015; 277: 388–97.

For citation:Butorova E.A., Stukalova O.V. Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases. Clinical review for general practice. 2021; 2: 16–20. DOI: 10.47407/kr2021.2.2.00037


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru